Medtronic PLC $MDT Shares Sold by Kiltearn Partners LLP

Key Points

• Kiltearn Partners trimmed its Medtronic stake by 7.0%, selling 16,200 shares and leaving it with 216,561 shares valued at about $20.63 million (Medtronic is 4.1% of Kiltearn’s portfolio and its 8th largest holding).
• Medtronic declared a quarterly dividend of $0.71 per share (annualized $2.84, ~3.1% yield) while its diabetes spinoff MiniMed raised about $560M in an IPO that nonetheless debuted below the offering price and left Medtronic owning roughly 90%—muting near‑term value‑unlock expectations.
• Operationally, Medtronic beat the quarter with $1.36 EPS (vs. $1.34 est.) and $9.02B revenue (vs. $8.89B est.), and set FY2026 guidance at $5.62–$5.66 EPS.

Kiltearn Partners LLP lowered its stake in shares of Medtronic PLC (NYSE:MDT - Free Report) by 7.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 216,561 shares of the medical technology company's stock after selling 16,200 shares during the quarter. Medtronic comprises 4.1% of Kiltearn Partners LLP's portfolio, making the stock its 8th largest holding. Kiltearn Partners LLP's holdings in Medtronic were worth $20,625,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Medtronic in the second quarter worth $1,432,698,000. Barclays PLC boosted its holdings in shares of Medtronic by 104.6% during the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company's stock worth $650,604,000 after buying an additional 3,492,192 shares during the period. Guinness Asset Management LTD acquired a new position in Medtronic in the 3rd quarter valued at $275,556,000. Vanguard Group Inc. grew its stake in Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company's stock valued at $11,062,693,000 after buying an additional 1,895,165 shares during the last quarter. Finally, Magellan Asset Management Ltd bought a new position in Medtronic in the 3rd quarter worth $126,347,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved quarterly cash dividend of $0.71 per share (annualized yield ~3.1%), supporting income investors and signaling confidence in cash flow. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Product/market progress in diabetes care with the MiniMed Go Smart MDI system launch in Europe, strengthening Medtronic’s connected diabetes portfolio and long‑term growth potential in CGM/smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Operational tech wins: updates on a Tempus clinical trial and expanded patient‑monitoring alliance with GE HealthCare, which could broaden distribution and adoption of Medtronic devices over time. Digital Alerts and Heart Valves: What Medtronic Investors Should Watch in New Tempus Trial Medtronic, GE HealthCare expand patient monitoring alliance
• Neutral Sentiment: MiniMed priced its IPO at $20 per share and raised about $560M, giving the standalone diabetes unit initial capital and a public valuation backdrop. This is a financing/structuring move that could be positive long term but is mixed near term. Medtronic's diabetes unit MiniMed raises $560 million in US IPO
• Negative Sentiment: MiniMed’s Nasdaq debut opened below the offering price (shares down ~4.8% on debut), which pressured sentiment toward the spinoff and Medtronic’s value‑unlock story — investors reacted to a softer than expected market reception. Medtronic's diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
• Negative Sentiment: Medtronic retains ~90% ownership of MiniMed after the IPO, limiting immediate capital release and potential near‑term accretion from the spinoff — this reduces the perceived benefit of the listing for MDT shareholders today. MiniMed (MMED) IPO Falls Flat as Medtronic (MDT) Spinoff Debuts Below Price

Medtronic Stock Performance

NYSE MDT opened at $90.83 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The firm has a market capitalization of $116.61 billion, a price-to-earnings ratio of 25.30, a P/E/G ratio of 2.28 and a beta of 0.71. The company's fifty day moving average is $98.69 and its two-hundred day moving average is $97.02. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.1%. Medtronic's dividend payout ratio is 79.11%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MDT. Jefferies Financial Group reissued a "hold" rating and set a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. CICC Research began coverage on Medtronic in a research note on Friday, January 30th. They issued an "outperform" rating on the stock. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a "neutral" rating in a research report on Wednesday, November 19th. TD Cowen restated a "buy" rating on shares of Medtronic in a research note on Friday, November 14th. Finally, Piper Sandler reaffirmed a "neutral" rating on shares of Medtronic in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $110.74.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is currently owned by company insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.